Ampligen price more than doubling in the US?
As many patients who are receiving Ampligen in the US already know, the price of Ampligen is set to dramatically increase.
Two patients I spoke with today said the price would more than double from $75 a vial to $200 per bottle. At their current dosages, that would raise the annual cost of Ampligen from $15,600 per year to $41,600 per year, not including the doctors’ fees for the infusion.
Many patients will either have to lower their dosages or forgo treatment altogether.
Ampligen is a treatment for Chronic Fatigue Syndrome that has not yet been approved by the FDA. It is currently available to some patients at a limited number of sites around the US under a cost recovery program previously known as “compassionate care.” It is delivered at a doctor’s office via a twice weekly intravenous infusion.
This is the first price increase since 1997. Under the cost recovery program, Hemispherx cannot make a profit on Ampligen, only recover its costs. According to Nancy McGrory, a representative from Hemispherx, the price increase was determined by an independent audit to determine the actual cost of manufacturing the drug.
Ampligen soon available in the European Union
Hemispherx also announced today that a Netherlands-based company called myTomorrows will be supplying Ampligen to some Chronic Fatigue Syndrome patients with “unmet medical need” through the Early Access Program (EAP).
Thomas K. Equels, Executive Vice Chairman and CFO of Hemispherx said “We are very pleased to be collaborating with myTomorrows to provide rintatolimod under these unique Early Access Programs. Not only will this collaboration create the possibility for physicians to use rintatolimod under certain circumstances, myTomorrows will collaborate with these physicians to capture data on patients treated and such data may add to our other efforts to gain full regulatory approval in Europe, Latin America, Australia, New Zealand as well as the U.S. and elsewhere.”